The risk or severity of adverse effects can be increased when Fimasartan is combined with Indapamide. Pargyline may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Droxicam. Prasterone sulfate may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Diltiazem is combined with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Darifenacin. The therapeutic efficacy of Indapamide can be decreased when used in combination with Duvelisib. The therapeutic efficacy of Indapamide can be decreased when used in combination with Pimecrolimus. The serum concentration of Indapamide can be increased when it is combined with Oxyphenonium. The therapeutic efficacy of Indapamide can be decreased when used in combination with Lumiracoxib. Indapamide may increase the QTc-prolonging activities of Anagrelide. The risk or severity of adverse effects can be increased when Indapamide is combined with Captopril. The metabolism of Indapamide can be decreased when combined with Dihydroergotamine. The therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac. The therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib. The metabolism of Indapamide can be decreased when combined with Voriconazole. Flunisolide may increase the hypokalemic activities of Indapamide. Equilin may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Metipranolol. Indapamide may increase the hypotensive activities of Risperidone. The serum concentration of Indapamide can be increased when it is combined with Atropine. Ciclesonide may increase the hypokalemic activities of Indapamide. Benmoxin may increase the hypotensive activities of Indapamide. Dihydralazine may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Nateglinide can be decreased when used in combination with Indapamide. Minaprine may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Indapamide. Indapamide may increase the hypotensive activities of Bepridil. The serum concentration of Indapamide can be increased when it is combined with Oxybutynin. The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Eprosartan. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Indapamide. Indapamide may decrease the excretion rate of Casein which could result in a higher serum level. Clobetasol propionate may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Irbesartan. Indapamide may increase the hypotensive activities of Platelet Activating Factor. Indapamide may increase the QTc-prolonging activities of Lumefantrine. The serum concentration of Indapamide can be increased when it is combined with Pentolinium. The serum concentration of Indapamide can be increased when it is combined with Tropicamide. The risk or severity of adverse effects can be increased when Propofol is combined with Indapamide. Fenoterol may increase the hypokalemic activities of Indapamide. Vilanterol may increase the hypokalemic activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Seratrodast. Indapamide may increase the hypotensive activities of Niguldipine. Guanadrel may increase the hypotensive activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Acebutolol. Indapamide may increase the QTc-prolonging activities of Clozapine. Betamethasone may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Minoxidil is combined with Indapamide. The therapeutic efficacy of Phenformin can be decreased when used in combination with Indapamide. Sertraline may increase the hyponatremic activities of Indapamide. Indapamide may increase the hypotensive activities of Guanethidine. Mifepristone may increase the QTc-prolonging activities of Indapamide. Indapamide may increase the hypotensive activities of Xylometazoline. The therapeutic efficacy of Indapamide can be decreased when used in combination with Kebuzone. The risk or severity of adverse effects can be increased when Indapamide is combined with Proscillaridin. Indapamide may increase the QTc-prolonging activities of Flupentixol. Rasagiline may increase the hypotensive activities of Indapamide. The therapeutic efficacy of Acarbose can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Apraclonidine. The risk or severity of adverse effects can be increased when Esmolol is combined with Indapamide. Indapamide may increase the QTc-prolonging activities of Dofetilide. The risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide. The serum concentration of Indapamide can be increased when it is combined with Luliconazole. The risk or severity of adverse effects can be increased when Indapamide is combined with Sulpiride. The metabolism of Indapamide can be decreased when combined with Saquinavir. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Bucillamine. Indapamide may increase the hypotensive activities of Theodrenaline. Flumethasone may increase the hypokalemic activities of Indapamide. Indapamide may increase the QTc-prolonging activities of Leuprolide. The serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide. Procaterol may increase the hypokalemic activities of Indapamide. Desvenlafaxine may increase the hyponatremic activities of Indapamide. Indapamide may increase the hypercalcemic activities of Paricalcitol. The risk or severity of adverse effects can be increased when Pipamperone is combined with Indapamide. Indapamide may increase the hypotensive activities of Epoprostenol. The metabolism of Indapamide can be decreased when combined with Fosamprenavir. The therapeutic efficacy of Indapamide can be decreased when used in combination with Salsalate. Indapamide may increase the QTc-prolonging activities of Eliglustat. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indapamide. The serum concentration of Indapamide can be decreased when it is combined with Dabrafenib. The therapeutic efficacy of Indapamide can be decreased when used in combination with Triptolide. The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine. The therapeutic efficacy of Indapamide can be decreased when used in combination with Fenbufen. The therapeutic efficacy of Indapamide can be decreased when used in combination with Nepafenac. Prednicarbate may increase the hypokalemic activities of Indapamide. Furazolidone may increase the hypotensive activities of Indapamide. Selegiline may increase the hypotensive activities of Indapamide. The serum concentration of Indapamide can be increased when it is combined with Dicyclomine. The risk or severity of adverse effects can be increased when Indapamide is combined with Acetyldigitoxin. Pregnenolone may increase the hypokalemic activities of Indapamide. Beclomethasone dipropionate may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Cilnidipine is combined with Indapamide. The risk or severity of adverse effects can be increased when Barnidipine is combined with Indapamide. Estrone sulfate may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Fentanyl is combined with Indapamide. Cortisone acetate may increase the hypokalemic activities of Indapamide. Indapamide may increase the QTc-prolonging activities of Perflutren. The therapeutic efficacy of Indapamide can be decreased when used in combination with Ibuprofen. Norepinephrine may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Nesiritide. Arformoterol may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Nisoldipine is combined with Indapamide. Thiopental may increase the orthostatic hypotensive activities of Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Carbaspirin calcium. Debrisoquin may increase the hypotensive activities of Indapamide. Estrone may increase the hypokalemic activities of Indapamide. Cryptenamine may increase the hypotensive activities of Indapamide. Indapamide may increase the hypotensive activities of Cafedrine. The therapeutic efficacy of Indapamide can be decreased when used in combination with Azelastine. The therapeutic efficacy of Indapamide can be decreased when used in combination with Flurbiprofen. The risk or severity of adverse effects can be increased when Indapamide is combined with Dipyridamole. Safrazine may increase the hypotensive activities of Indapamide. The risk or severity of adverse effects can be increased when Indapamide is combined with Empagliflozin. The risk or severity of adverse effects can be increased when Indapamide is combined with Diazoxide. Dexamethasone may increase the hypokalemic activities of Indapamide. The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Indapamide. The risk or severity of adverse effects can be increased when Isoflurane is combined with Indapamide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole. The therapeutic efficacy of Indapamide can be decreased when used in combination with Etofenamate. Rimexolone may increase the hypokalemic activities of Indapamide. Dobutamine may increase the hypokalemic activities of Indapamide. Indapamide may increase the QTc-prolonging activities of Zuclopenthixol. The therapeutic efficacy of Indapamide can be decreased when used in combination with Balsalazide. The therapeutic efficacy of Indapamide can be decreased when used in combination with Chloroquine. Pirlindole may increase the hypotensive activities of Indapamide.